Literature DB >> 25200885

[Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses].

M C Hinsch1, D Reichelt, I W Husstedt.   

Abstract

Among patients with human immunodeficiency virus (HIV) infections psychiatric disease poses a particular challenge for caregivers. Neuropsychiatric side effects of efavirenz have been described in up to 40% of patients showing dizziness, insomnia, unusual dreams, mood instability, personality alterations and thought disorders. In immigrants from Africa and South America these side effects may be related to elevated plasma concentrations of efavirenz due to polymorphisms of cytochrome P450 isozymes (especially G516T). Alleles for these polymorphisms are more frequent in African and South American patients. We report a case of a 52-year-old patient from Guinea who was referred to the department of neurology under the diagnosis of HIV-associated neurocognitive disorder (HAND). Since the start of combined antiretroviral therapy (cART) including efavirenz the patient had suffered severe personality alterations, acoustic and visual hallucinations and delusions which led to discrimination and reduced quality of life. Diagnostic procedures including magnetic resonance imaging (MRT) and spinal fluid analysis resulted in normal values and did not explain the disease. After switching to nevirapin instead of efavirenz the psychotic symptoms disappeared within 5 days.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25200885     DOI: 10.1007/s00115-014-4157-9

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  22 in total

Review 1.  Implications of efavirenz for neuropsychiatry: a review.

Authors:  G I T Cavalcante; V L M Capistrano; F S D Cavalcante; S M M Vasconcelos; D S Macêdo; F C F Sousa; D J Woods; M M F Fonteles
Journal:  Int J Neurosci       Date:  2010-10-22       Impact factor: 2.292

2.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

3.  AIDS/HIV infection, comorbid psychiatric illness, and risk for subsequent suicide: a nationwide register linkage study.

Authors:  Cun-Xian Jia; Lars Mehlum; Ping Qin
Journal:  J Clin Psychiatry       Date:  2012-09-04       Impact factor: 4.384

4.  Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.

Authors:  L B Avery; N Sacktor; J C McArthur; C W Hendrix
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

5.  Evaluation of mental status HIV-infected patients: implications for treatment.

Authors:  Y H Jin; A Potthoff; J Xu; W J Yu; K Liu; N C Weng; N H Brockmeyer; N P Wu
Journal:  Curr HIV Res       Date:  2012-09       Impact factor: 1.581

6.  Acute psychosis under efavirenz in a HIV patient.

Authors:  Haïfa Zalila; Hend Elloumi; Nesrine Gaha; Rim Ghachem; Imen Ghazali; Afif Boussetta
Journal:  Tunis Med       Date:  2010-02

7.  Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.

Authors:  Maria Dobrinas; Séverine Crettol; Beatrice Oneda; Rachel Lahyani; Margalida Rotger; Eva Choong; Rubin Lubomirov; Chantal Csajka; Chin B Eap
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

Review 8.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

9.  Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

Authors:  Hiroyuki Gatanaga; Tsunefusa Hayashida; Kiyoto Tsuchiya; Munehiro Yoshino; Takeshi Kuwahara; Hiroki Tsukada; Katsuya Fujimoto; Isao Sato; Mikio Ueda; Masahide Horiba; Motohiro Hamaguchi; Masahiro Yamamoto; Noboru Takata; Akiro Kimura; Takao Koike; Fumitake Gejyo; Shuzo Matsushita; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Clin Infect Dis       Date:  2007-09-24       Impact factor: 9.079

10.  Central nervous system disorders after starting antiretroviral therapy in South Africa.

Authors:  Valerie Asselman; Friedrich Thienemann; Dominique J Pepper; Andrew Boulle; Robert J Wilkinson; Graeme Meintjes; Suzaan Marais
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.